Drug intelligence / Profile preview

Italfarmaco HDAC Class I inhibitor (fibrosis)

Development stage: Preclinical
Lead developer: Italfarmaco
Modality: Small Molecules
Administration: Oral

Overview

Italfarmaco's undisclosed HDAC Class I inhibitor is a small molecule in preclinical development for the treatment of fibrosis. The drug targets Class I histone deacetylases (HDACs), which are enzymes that remove acetyl groups from lysine residues on histones, thereby regulating gene transcription. In fibrotic conditions, Class I HDACs are often involved in the activation of fibroblasts into myofibroblasts and the subsequent overproduction of extracellular matrix components. By inhibiting these enzymes, the candidate aims to suppress pro-fibrotic gene expression and reduce tissue scarring.

Targets

HDAC1 (Histone Deacetylase 1)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)

Beyond the preview

Go deeper on Italfarmaco HDAC Class I inhibitor (fibrosis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Italfarmaco HDAC Class I inhibitor (fibrosis).